MK-8776 (SCH 900776)

MK-8776 (SCH 900776)は、選択的なChk1</b> 阻害剤で、IC50 が 3 nMです。

5 5 1レビュー
価格 在庫  
USD 264 In stock
USD 296 In stock
USD 466 In stock
USD 1222 In stock
USD 3112 In stock

MK-8776 (SCH 900776) 化学構造
分子量: 376.25



Quality Control & MSDS


  • Combination Therapy
  • Compare Chk Inhibitors
  • 研究分野



情報 MK-8776 (SCH 900776)は、選択的なChk1</b> 阻害剤で、IC50 が 3 nMです。
目標 Chk1
IC50 3 nM [1]
In vitro試験 SCH 900776 is a less potent inhibitor of Chk2 and CDK2 with IC50 of 1.5 μM and 0.16 μM, respectively. SCH 900776 shows no significant inhibition of cytochrome P450 human liver microsomal isoforms 1A2, 2C9, 2C19, 2D6, and 3A4. SCH 900776 induces a dose-dependent loss of DNA replication capability 24 hours after hydroxyurea exposure. SCH 900776 enhances the γ-H2AX response of hydroxyurea, 5-fluoruracil, and cytarabine. In combination with an antimetabolite, SCH 900776 induces accumulation of γ-H2AX within 2 hours, indicative of replication fork collapse and double stranded DNA breaks. Additionally, SCH 900776 suppresses accumulation of the Chk1 pS296 autophosphorylation in a dose-dependent manner. Exposure of proliferating WS1 cells to SCH 900776 is associated with rapid, dose-dependent accumulation of Chk1 pS345, indicating that cycling populations of normal cells induce Chk1 pS345 following exposure to SCH 900776 as part of a futile cycle, perhaps driven by AT-family kinases and DNA-PK.[1]
In vivo試験 Administered 30 minutes after gemcitabine, 4 mg/kg SCH 900776 is sufficient to induce the γ-H2AX biomarker while 8 mg/kg leads to enhanced tumor pharmacodynamic and regression responses relative to gemcitabine or SCH 900776 alone. Dose escalation of SCH 900776 (16 mg/kg and 32 mg/kg) induces incremental improvements in tumor response. Importantly, doses of SCH 900776 associate with robust biomarker activation and improved tumor response are not associated with enhanced toxicity of gemcitabine on hematological parameters in BALB/c mice. [1]
臨床試験 A Phase I study of SCH 900776 with and without Gemcitabine in patients with solid tumors or lymphoma has been completed.

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

Chk1 SPA assay An in vitro assay utilizing recombinant His-Chk1 expressed in the baculovirus expression system as an enzyme source and biotinylated peptide based upon CDC25C as substrate. His-Chk1 is diluted to 32 nM in kinase buffer containing 50 mM Tris pH 8.0, 10 mM MgCl2, and 1 mM DTT. CDC25C (CDC25 Ser216 C-term biotinylated peptide) peptide is diluted to 1.93 μM in kinase buffer. For each kinase reaction, 20 μL of 32 nM Chk1 enzyme solution and 20 μL of 1.926 μM CDC25C are mixed and combined with 10 μL of SCH 900776 diluted in 10% DMSO, making final reaction concentrations of 6.2 nM Chk1, 385 nM CDC25C and 1% DMSO after addition of start solution. The reaction is started by addition of 50 μL of start solution consisting of 2 μM ATP and 0.2 μCi of 33P-ATP, making a final reaction concentration of 1 μM ATP, with 0.2 μCi of 33P-ATP per reaction. Kinase reactions run for 2 hours at room temperature and are stopped by the addition of 100 μL of stop solution consisting of 2 M NaCl, 1% H3PO4, and 5 mg/mL Streptavidin-coated SPA beads. SPA beads are captured using a 96-well GF/B filter plate and a Filtermate universal harvester. Beads are washed twice with 2 M NaCl and twice with 2 M NaCl with 1% phosphoric acid. Signal is then assayed using a TopCount 96-well liquid scintillation counter. Dose-response curves are generated from duplicate 8 point serial dilutions of SCH 900776. IC50 values are derived by nonlinear regression analysis.

動物実験: [1]

動物モデル Female nude mice injected subcutaneously with A2780 or MiaPaCa2 cells
製剤 Formulated in 20% hydroxypropyl β-cyclodextrin
投薬量 ~50 mg/kg
管理 Administered intraperitoneally



Download MK-8776 (SCH 900776) SDF
分子量 376.25


CAS No. 891494-63-6
別名 N/A
溶解度 (25°C)
  • DMSO 3 mg/mL
  • 水 <1 mg/mL
  • エタノール <1 mg/mL
保管 2年 -20°C
6月-80°Cin DMSO
化学名 6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-((R)-piperidin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine


カスタマーレビュー (1)

Click to enlarge
Source MK-8776 (SCH 900776) purchased from Selleck
Method Western blot
Cell Lines HeLa cells
Concentrations 1-10 uM
Incubation Time 24 h
Results CHK1 phosphorylation increased at 1uM of MK-8776 (SCH900776), possibly due to a negative feedback, or to prevention of phosphatase proximity. At 10uM, CHK1 phosphorylation was inhibited.



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related Chk 阻害剤

  • PD0332991 HCl

    Palbociclib (PD-0332991) HClはCdksを抑制、Cdk4/ cyclin D1とCdk6/ cyclin D2に作用する時、IC50がそれぞれ11と16nMになる。

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032)は、CDK2、CDK7とCDK9の新しくて、強力で、選択的なcdk阻害剤で、 IC50 がそれぞれ 38 nM、 62 nM 、 4 nMです。

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib,CYC202)は有効な細胞週期卵白の依存性キナーゼ選択阻害剤、cdc2/ cyclin B、cdk2/ cyclin A、cdk2/ cyclin Eとcdk5/ p53に作用する時、IC50それぞれ0.65、0.7、0.7と0.16μM。

  • Flavopiridol (Alvocidib)

    Flavopiridol (Alvocidib)は、CDK1、CDK2、CDK4、CDK5、CDK6とCDK9を目標としている汎cdk阻害剤で、IC50 がそれぞれ 30 nM、 170 nM、 100 nM、 170 nM、 80 nM と 20 nMです。

  • JNJ-7706621


  • PHA-793887

    PHA-793887は、CDK2、CDK5とCDK7の新しくて強力な阻害剤で、IC50 がそれぞれ 8 nM、 5 nM と 10 nMです。

  • AT7519

    AT7519は、新しい小分子です。それは、マルチ・サイクリン依存的なキナーゼ阻害剤で、CDK1/cyclin B、 CDK2/Cyclin A、 CDK3/Cyclin E、 CDk4/Cyclin D1、 CDk5/p35、 CDK6/Cyclin D3に作用すると、IC50が それぞれ210 nM、47 nM、360 nM、100 nM、13 nM、170 nM になる。

  • AZD7762


  • BS-181 HCl

    BS-181 HClはCDK7高度選択阻害剤、IC50が21nMになる。

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionateは、非常に特定のCDK4CDK6の阻害剤で、 IC50 がそれぞれ11 nM と 16 nMです。


Tags: MK-8776 (SCH 900776)を買う | MK-8776 (SCH 900776)供給者 | MK-8776 (SCH 900776)を購入する | MK-8776 (SCH 900776)費用 | MK-8776 (SCH 900776)生産者 | オーダーMK-8776 (SCH 900776) | MK-8776 (SCH 900776)代理店